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1 |  BACKGROUND
Clinical laboratories and clinicians follow strict policies for 
resulting and storage of data from clinical testing. Usually, 
the ordered test is clearly identified and resulted in a way 
that the care teams can readily access them. The goal of 
clear, accessible records has become even more widespread 
with the advent of the electronic health record (EHR). While 
genetic information in the EHR has become mainstream, 
a few genetic tests still defy these practices for the sake of 
confidentiality and to address clinician and patient concerns 
about stigmatization and potential discrimination, such as 
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Background: Clinical care teams providing presymptomatic genetic testing often 
employ advanced confidentiality practices for documentation and result storage. 
However, patient requests for increased confidentiality may be in conflict with the 
legal obligations of medical providers to document patient care activities in the elec-
tronic health record (EHR). Huntington disease presents a representative case study 
for investigating the ways centers currently balance the requirements of EHRs with 
the privacy demands of patients seeking presymptomatic genetic testing.
Methods: We surveyed 23 HD centers (53% response rate) regarding their use of the 
EHR for presymptomatic HD testing.
Results: Our survey revealed that clinical care teams and laboratories have each 
developed their own practices, which are cumbersome and often include EHR avoid-
ance. We found that a majority of HD care teams record appointments in the EHR 
(91%), often using vague notes. Approximately half of the care teams (52%) keep 
presymptomatic results of out of the EHR.
Conclusion: As genetic knowledge grows, linking more genes to late‐onset condi-
tions, institutions will benefit from having professional recommendations to guide 
development of policies for EHR documentation of presymptomatic genetic results. 
Policies must be sensitive to the ethical differences and patient demands for presymp-
tomatic genetic testing compared to those undergoing confirmatory genetic testing.
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in insurability and employment. While there are a hand-
ful of these conditions, including frontotemporal dementia 
[OMIM: 600274] and autosomal dominant Alzheimer dis-
ease [OMIM: 607822, 104300], the most established is the 
protocol (HDSA, 2016) for presymptomatic genetic testing 
for the presence of the expanded trinucleotide repeat asso-
ciated with Huntington disease (HD) [OMIM: 143100]. HD 
is an autosomal dominant neurodegenerative disorder asso-
ciated with an expansion of a polymorphic CAG trinucleo-
tide repeat in exon 1 of HTT (Gusella et al., 1983; HDCRG, 
1993). While the disease is typically late‐onset, most com-
monly between the ages of 30–50, individuals of any age can 
have HD (Roos, 2010). HD is invariably fatal following a sev-
eral‐decade progressive decline in motor control, cognitive 
faculties and behavioral disturbances. Direct testing in symp-
tomatic patients and presymptomatic testing in at‐risk family 
members has been available since 1993. Whereas HD testing 
is widely available and fairly routine (Losekoot et al., 2013), 
uptake of testing remains low among healthy people at risk 
for HD, with fewer than 10% of at‐risk adults in the United 
States getting tested. This number is only slightly higher in 
countries with a socialized system of health care; in the UK 
approximately 17% of people at‐risk for HD are tested (Baig 
et al., 2016).
Due to the nearly 100% penetrance of this adult‐onset 
condition, the decision for an individual to undergo test-
ing, especially prior to the onset of symptoms, is diffi-
cult, as the results may not just affect their life and family 
but could also produce serious psychosocial reactions and 
lead to future financial planning, educational, and em-
ployment complications (Divino et al., 2013). The Genetic 
Information Nondiscrimination Act of 2008 (GINA, 2009) 
and the Affordable Care Act (ACA, 2010) protect individu-
als from health insurance discrimination; however, other in-
surance products such as disability, life, and long‐term care 
are not protected by these laws. Thus, a positive presymp-
tomatic HD test result may render an otherwise healthy in-
dividual uninsurable. Stakeholders such as the Huntington's 
Disease Society of America (HDSA), the American Society 
of Human Genetics (ASHG), and the American College of 
Medical Genetics and Genomics (ACMG) (ACMG/ASHG, 
1998), have stressed extensive pre‐test counseling and confi-
dential testing to “protect the well‐being of individuals who 
choose to be tested” (HDSA, 2016). However, maintaining 
strict confidentiality of test results is difficult, especially in 
the age of the EHR, and may actually compromise patient 
care by restricting access to essential diagnostic information.
The field of genetics has wrestled with the possibility of 
discrimination since the advent of testing for sickle cell dis-
ease (Fulda & Lykens, 2006). Since HD was one of the first 
genes for which presymptomatic individuals could choose to 
be tested, protocols were established to maintain utmost con-
fidentiality. Results are generally not withheld from the EHR 
except for certain genetic results which are deemed confiden-
tial, which is in line with “genetic exceptionalism” (Murray, 
1997), namely the practice of treating genetics results dif-
ferently based on a paternalistic view of patient care. Even 
though there was a precedent for constraint in the early days 
of HIV testing (Malmberg, Phan, Harmon, & Nauert, 2012; 
Williams, 2011), resulting of HIV status in a secure EHR is 
generally promoted over paper records, so as to help the indi-
vidual with their personal care and as a mechanism for public 
health reporting (Malmberg et al., 2012).
If strict confidentiality is to be maintained, special pre-
cautions must be in place from the moment the patient enters 
the clinic, from scheduling, through test ordering, resulting, 
to post‐test disclosure and genetic counseling; however, con-
fidentiality of the laboratory test report is a moot point if the 
information ends up in a clinician's note. This survey of US 
clinical care teams who routinely order HD presymptomatic 
testing of individuals addresses the use of the EHR through-
out the process as a means to reveal the day‐to‐day issues 
with confidentiality in light of EHR use. The ACMG and 
ASHG statements regarding HD testing only speak to the 
technical standards and guidelines of the test itself (ACMG/
ASHG, 1998) and do not offer recommendations for how the 
care team handles the test order or results. The HDSA test-
ing protocol (HDSA, 2016) addresses standards for educating 
and supporting individuals being tested; however, it does not 
offer standards for managing the legal obligations and chal-
lenges of maintaining confidentiality in the EHR. Lastly, the 
reporting of a single type of test differently because of con-
fidentiality concerns may need to be examined, and a more 
practical protocol may need to be established.
2 |  METHODS
2.1 | Ethical compliance
Neither certification of exemption from UCLA IRB re-
view nor UCLA IRB approval of the proposal and survey 
questions were required since the activities did not involve 
“human subjects” research as defined by federal regulations 
for human subject protections.
2.2 | Survey procedures
We contacted 43 United States Centers of Excellence listed 
on the HDSA website (Huntington's Disease Society of 
America, 2019) to query their policies regarding availabil-
ity of genetic results for presymptomatic individuals. We 
emailed the contact person listed on the site, and those who 
did not respond were contacted one additional time. Twenty‐
three clinical care teams from 17 states offering HD genetic 
testing agreed either to a phone interview or to fill out a writ-
ten questionnaire regarding their current practices. The single 
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member representing the common practice at their institution 
included genetic counselors, social workers or clinicians. For 
the phone interviews, the survey was sent prior to the con-
versation, filled out based on their statements, and responses 
were confirmed during the phone call. During the phone in-
terviews, representatives were generally more open to shar-
ing their concerns and giving examples of disparities in this 
testing population (see Discussion). Two centers rejected the 
survey because they do not currently perform presympto-
matic genetic testing. Eleven never responded to correspond-
ence, and two responded but did not want to participate. In 
five cases, the contact person responded to the email, indicat-
ing they were no longer involved with the listed center and 
offered to forward the request to the correct person; however, 
no response from that center was ever received.
Questionnaires focused on how the HD gene analysis is 
ordered, resulted, and stored. The questionnaire was multi-
ple choice, and answers were compiled and counted. Each 
member representing their institution was instructed to an-
swer based on how their institution handles presymptomatic 
individuals (Figure S1). All answers were kept confidential.
3 |  RESULTS
All responding centers perform presymptomatic testing for 
expanded HD alleles. A minority of institutions (39%) have 
different procedures for individuals choosing to use self‐pay 
versus insurance, including sending the test to a different 
laboratory and documentation in the EHR (Figure 1). Two 
institutions do not allow for a self‐pay option, and one does 
not bill insurance for their services/testing. Approximately 
half of the patients (52%) choose to use insurance when pos-
sible, and multiple institutions noted that the percentage of 
patients choosing insurance to cover the test has been in-
creasing in the past few years. Some institutions noted that 
the majority of the individuals choose insurance coverage for 
the initial encounter with an ordering physician, even if the 
individual chooses self‐pay for the laboratory test. A majority 
of institutions (56%) document encounters in the EHR using 
the individual's true identity, and 30% of centers allow for the 
individual's choice of true identity or a pseudonym. A minor-
ity of institutions (9%) have avoided EHR use completely. 
However, one of the centers avoiding the EHR is unique as 
it is a research center rather than a clinical center, thus al-
lowing it this freedom. Of the institutions documenting the 
individuals in the EHR, a majority of clinicians (67%) write 
a clear, brief note in the EHR, discussing the testing ordered 
and family history, and of the remaining 33%, the clinician 
note does not state the testing in question with some referring 
to a paper note (“shadow chart”) accessible offline.
A majority of institutions (61%) order testing through 
the EHR. Of those, 57% order the test under “HD testing”. 
The remaining (43%) teams order tests that are not specific 
to HD, such as “Genetic Analysis,” “Special Procedure” or 
“Molecular Pathology”. In the latter cases, the care team 
wrote in “HD testing”. A minority of institutions (39%) order 
by paper requisition or through a laboratory portal not linked 
to the individual's EHR. A majority (65%) uses a reference 
laboratory for testing, some noting this is unique only to 
their self‐pay patients and not their patients using insurance 
coverage. The remaining centers (35%) conduct the testing 
F I G U R E  1  Results from a clinical care team survey on the process of ordering, resulting, and storage of presymptomatic genetic testing for 
Huntington disease. Blue represents tasks completed on the EHR and orange represents tasks completed off the EHR
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in‐house. Interestingly, whether or not the care team ordered 
the test through the EHR is not correlated with the type of 
laboratory (in‐house or reference) running the test (p = .91).
Of those using a reference laboratory, 47% receive the re-
sults via the EHR, and 53% receive results either via fax or 
through a laboratory portal. Of those care teams utilizing an 
in‐house laboratory, most (75%) received a paper copy, and 
25% of the teams noted the results came through the EHR. No 
matter the type of laboratory (reference or in‐house), the test 
results are accessible to all practitioners in the EHR at 48% 
of total institutions, with 54% of these releasing results in 
the EHR after the care team has the results appointment with 
the individual. A slim majority of institutions (52%) store the 
results outside of the EHR, either in a locked cabinet (91%) 
or in electronic form (9%). Two institutions upload the results 
into the EHR depending on discussions with the patient.
We asked the institutions for their impression as to the 
confidentiality concerns of patients seeking presymptomatic 
testing. Answers ranged from adamant about patient confi-
dentiality to being content with having results in the EHR 
(Figure S1). A minority of institutions (30%) noted the lat-
ter; however, three centers do not have an option to avoid the 
EHR. Those institutions with the option of anonymity noted 
that many to all their patients are concerned enough to have 
a discussion. Multiple institutions chose all three options for 
this question as, not surprisingly, their patients have different 
opinions as to confidentiality of their results.
4 |  CONCLUSION
Strict maintenance of confidentiality in the age of universal 
EHR use is difficult. Institutional adherence to the laws of 
medical privacy is typically in conflict with the patient's un-
derstanding of and wishes for privacy. In the world of EHRs, 
particularly nearly universal medical record access when 
multiple unrelated institutions use the same EHR platform, 
routine clinical care may also infer an ability for providers of 
all types to have unfettered access to genetic testing results. 
Many patients will view this as a breach of their confidential-
ity when in reality this access is fully within the bounds of 
HIPAA and other privacy policies. Our survey results suggest 
that HD centers have a desire to protect the confidentiality 
of patients; however, this is becoming increasingly difficult 
with the modernization of medical records through EHRs and 
legal requirements. Still, centers often create workarounds to 
avoid notice in the EHR, which in some cases places an un-
necessary burden on the laboratory and clinic at a time when 
efficiency in the EHR is preferred, necessary, and sometimes 
mandated by the hospital/institution to receive reimburse-
ments from the US government (ARRA, 2009). These work-
arounds also increase the chances for identification errors, 
inability to retrieve results when needed, loss of records, and 
miscommunication. Since testing protocols (HDSA, 2016) 
do not address the laws and policies regarding maintenance 
of records, each individual center must establish methods 
within the bounds of their larger medical institution. While 
this survey addresses HD as an example, establishing best 
practices for testing and reporting would be helpful for other 
cases of presymptomatic genetic testing of individuals har-
boring detrimental variants or expanded alleles in highly pen-
etrant, late‐onset diseases.
4.1 | Pre‐test appointments
Starting with the act of booking the initial neurologic or ge-
netics appointment, individuals must decide whether or not 
to use insurance to pay for the appointment(s). In many cases, 
for insurance to cover the appointment(s), a note and (sus-
pected) diagnosis must be documented in the EHR. Centers 
that document appointments in the EHR ranged from stat-
ing “see paper note” to stating “family history of neurologic 
disorder” or “family history of HD”, although most stated 
they keep the note as brief as possible. One clinician who 
does not mention HD in his note in order to conform to long‐
standing practices at that center felt that not being explicit 
as to the testing did not represent appropriate medical care. 
A possible solution could be an access‐limiting note, which 
would deem such notes as private and appear to maintain 
the argument of “genetic exceptionalism” (Green & Botkin, 
2003; Murray, 1997). Access‐restricted notes were utilized 
at one center; however, recently their institution has blocked 
this feature, and all notes are available to the EHR in their 
entirety. In order to achieve true informed consent for HD 
testing, centers must make an effort to explain to the pa-
tient, prior to scheduling their initial testing appointment(s), 
the practices and limitations of the documentation and its 
visibility in the EHR. This is a difficult task, particularly 
as these practices and views of “genetic exceptionalism” 
change over time (Evans & Burke, 2008; Murray, 2019; 
Rothstein, 2007).
4.2 | Testing order name
Clinical laboratory test ordering needs to be clear and con-
cise to avoid mistakes between the care team and laboratory 
interface. In many cases in the medical field, the test names 
are overly complex and full of abbreviations leading to con-
fusion (Passiment et al., 2013); however, this survey shows 
the opposite may have the same effect. One institution uses 
the term “Genetic Analysis,” which is a specific “unwritten 
code” for HD testing at that laboratory. This unclear order-
able may lead to inaccurate orders, which must then be clari-
fied. For example, clinicians not familiar with the “code” may 
use this entry to order a multitude of genetic tests, for exam-
ple, Lynch syndrome. The laboratory then may contact the 
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clinician by email to confirm the test, stating they received 
an order for “Genetic Analysis” and specifically stating HD 
testing in the email, thus breaking the confidentiality that was 
originally intended by the discreet name of the test order.
A minority (39%) of care teams avoid the EHR for order-
ing the test, opting for paper requisition forms or ordering 
through a separate laboratory portal. Thus, they are able to 
avoid the confidentiality breach that may occur by ordering 
the test through the patient's personal EHR. However, some 
clinicians and informaticists (Jamoom, Patel, Furukawa, & 
King, 2014) argue that  ordering through the EHR allows 
for efficient use of resources: lower costs, fewer errors, and 
quicker turn‐around time.
4.3 | Storage of results
When the test is resulted, most institutions do not place re-
sults in the EHR, instead handing out a paper copy. While this 
maintains confidentiality, avoiding the EHR places a burden 
on the individual and the care team to keep results easily ac-
cessible. In general, genetic testing reports must be retained 
by the laboratory for a minimum of 10  years (Schwartz, 
1999). However, individuals may undergo presymptomatic 
HD testing many years prior to presenting symptoms of the 
disease. In addition, a recent survey found the age of pre-
symptomatic testing has decreased, thus resulting in a longer 
period of time between testing and symptoms (Holman et al., 
2018). EHR is more permanent, allowing for easier mainte-
nance of results.
A majority of care teams choose to keep results in a locked 
cabinet, which is counter to recommendations that storage 
of genetic results be in the EHR (ARRA, 2009; Botkin et 
al., 2015; Shoenbill, Fost, Tachinardi, & Mendonca, 2014). 
While one can argue that the storage cabinet is safer, it places 
excessive burden on the staff member charged with security. 
Beyond those concerns, as defined by CLIA and HIPAA, the 
patient has a right to access their test reports upon request, 
and laboratories subject to CLIA must be able to provide 
copies of the requested completed test (CMS et al., 2014; 
Schwartz, 1999). Individuals returning decades post‐testing 
for a copy of their results will result in an overwhelming 
amount of work to retrieve the correct files, which in the in-
terim may have been relocated to remote sites or stored on 
media that is no longer readable.
4.4 | Care team accessibility
Accessibility of testing results to the care team is a sub-
stantial concern. While the EHR is intended to provide an 
accurate medical history, there is the worry of intended and 
unintended views of protected health information (PHI). 
State laws on the subject of who can receive/access re-
sults vary across the US, with a majority allowing for only 
medical professionals who “need to know” having access 
to results. In this matter, one could argue  that placement 
of any type of test where the results were deemed to need 
a higher level of protection should not be in a fully acces-
sible EHR.
Maintaining confidentiality of laboratory testing is not 
new to the medical records field. Beyond genetics, adoles-
cent care, mental health, and substance abuse treatment 
teams have been the most vocal about confidentiality of the 
EHR, and thus have built‐in privacy functions in the soft-
ware platform used. These teams have created “safeguards” 
to avoid intended and unintended views of patient PHI, 
such as, “soft barriers” or “hard stops”. “Break‐the‐glass” 
is intended to warn physicians that they are embarking on 
information deemed more private. Those who do “break‐
the‐glass” are then tracked and if the access to that infor-
mation was deemed inappropriate, may lead to reprimand 
or termination based on the breach severity. However, this 
feature is generally seen as a pseudo‐protection since it 
does not block access for any clinician, nurse, medical stu-
dent or laboratorian using the interface. Thus, it is only a 
perceived protection.
The “hard stops” refer to a block in the information, such 
that only those designated by the program can have access 
to such data. One principal reason the EHR was developed 
was to make data sharing easier with other clinicians; thus, 
every informatically placed block leads to a decrease in the 
availability of information to another care team who may be 
called upon to treat the patient without knowing the histori-
cal context (Shenoy & Appel, 2017). Some commented that 
it is important for any future care team to know HD results in 
case an individual becomes symptomatic and needs proper 
care. Thus, keeping genetic test results out of the EHR may 
have the potential to cause delays in care, misdiagnoses, 
unnecessary repeat testing, or increase costs of care in the 
future.
Knowledge of rare, highly penetrant, late‐onset genetic 
diseases may be relatively low in general medical practice. 
One study found  that few providers felt knowledgeable on 
the subject of genetics, interpreting genetic test results and 
able to care for patients with genetic testing (Hauser, Obeng, 
Fei, Ramos, & Horowitz, 2018). For example, a positive pre-
symptomatic test result for HD is not the same as a clinical 
diagnosis of HD.
EHR confidentiality extends beyond the health of just the 
individual. Some states/insurance carriers will cover in vitro 
fertilization (IVF)/preimplantation genetic diagnostic testing 
(PGD) (Drazba, Kelley, & Hershberger, 2014); however, to 
cover such testing, the genetic variant must be on record. The 
same would apply for entry into any clinical trials of HD pre-
vention or therapy. In one case cited in the survey results, 
the couple decided that having the positive HD genetic test 
recorded in the EHR was a much greater risk than paying 
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out‐of‐pocket for IVF with PGD testing, a process known to 
cost tens to hundreds of thousands of dollars (Goldman et al., 
2018). Thus, if the EHR included this information in a more 
confidential matter, families may be more comfortable with 
recording this information in their EHR and not have to make 
these difficult decisions.
Many institutions surveyed mentioned the results are 
immediately placed in the EHR but withheld completely 
or for a period of time from the patient portal. No specific 
laws or regulations have been established to address the 
degree of information suppressed from a patient‐accessi-
ble portal. HIPAA privacy rule deems that patients have 
a right to their laboratory results, and these results should 
not be withheld based on the sensitive nature or potential 
for causing distress to the individual (CMS et al., 2014). 
Thus, it may behoove professional bodies to decide if all 
genetic results be available in a patient portal to allow pa-
tients to access their data which either they or their insur-
ance paid for.
4.5 | Limited professional guidance
We found a wide range of institutional protocols rang-
ing from full disclosure (clinician note, test ordered and 
results) to absence in the EHR. In an era of reliance on 
the EHR, the reporting of a single test differently from all 
other laboratory results because of confidentiality concerns 
may need to be examined and a more practical and uniform 
protocol may need to be established by professional bod-
ies. Survey responses revealed a number of other concerns, 
such as cumbersome storage and retrieval of test results, 
lost results, vague or misleading clinical notes, additional 
intralaboratory burdens, and, now that targeted therapies 
(Dickey & La Spada, 2018) for HD are emerging, loss of 
eligibility for tested patients to enter clinical trials due to 
delays in obtaining test results outside of EHRs. The rec-
ommended HDSA protocol for testing suggests a level of 
confidentiality that was effective when all documentation 
was maintained on paper. However, with many hospitals 
and laboratories predominantly using EHRs for all appoint-
ments, notes, communications with patients, and testing, 
we found a large spectrum of practices are occurring in the 
field.
Beyond presymptomatic HD testing, institutions also 
need to consider which other genetic conditions deserve this 
highest level of confidentiality, thus begging  the question 
of how to make the determination and who should decide. 
Testing for asymptomatic carriers of BRCA variants has 
been done for roughly the same amount of time; however, 
those results are not concealed from the EHR (though some 
patients still prefer to pay out of pocket and use a pseud-
onym). Of course, hereditary breast/ovarian cancer is a 
quite different disease with lower penetrance and far more 
options for prevention and treatment. Beyond genetics, HIV 
status, which early in the epidemic was kept strictly confi-
dential, is now encouraged to be documented in the EHR 
under the argument of effective care for the person (Green 
& Botkin, 2003; Herwehe et al., 2012; Safran et al., 1995). 
Recommended criteria to guide clinical teams and labora-
tories when establishing a protocol for confidentiality of 
predictive genetic testing do not exist. Therefore, profes-
sional recommendations for the appropriate use of EHRs to 
document, order, and report genetic testing for late‐onset, 
highly penetrant conditions in presymptomatic individuals 
are needed to help standardize and optimize current clinical 
and laboratory practices.
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